AstraZeneca Stock - Weekly review and sector context after recent pullback
Published on 06/19/2026 at 14:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 14:00 CET. Details in the imprint.
AstraZeneca (US6549022043) remains one of the largest global pharma groups by market value. The stock has recently slipped from earlier highs, prompting a closer look at its weekly performance and its positioning against big-pharma peers.
All news and key data on AstraZeneca stock
Further background, filings and news flow on AstraZeneca stock can be found in the dedicated topic area and on the company’s investor-relations pages.
How AstraZeneca shares performed this week
On the US market, AstraZeneca’s American depositary shares last closed at about $174.90, after a decline of roughly 1.7% in the latest session, according to recent trading data. A recent market summary highlights the move versus broader US indices.
In London, where AstraZeneca is a key healthcare weight, the stock recently traded around 13,300 pence, roughly 15% below its 52-week high of 15,732 pence reached in February 2026. Market data from the Financial Times underlines that distance from the peak.
Weekly review and sector comparison
Over the past several sessions, AstraZeneca shares have lagged the broader US market, which recently notched fresh gains in the Standard & Poor's 500 index, according to market commentary. The same overview notes that AstraZeneca ended lower on a day when the S&P 500 advanced.
Despite the softer short-term performance, AstraZeneca remains a heavyweight in global pharma, with a market capitalization near $270 billion on a US basis. Data from a recent quote snapshot shows a market cap around $269 billion and a valuation in the mid-20s times earnings.
What the company sells
AstraZeneca generates most of its revenue from prescription medicines in oncology, cardiovascular, renal and metabolic diseases, and respiratory conditions. Flagship products include cancer therapies such as Tagrisso and Lynparza, alongside other specialty medicines developed in-house and with partners.
Where the stock trades today
The shares of AstraZeneca (US6549022043) trade in the US as ADRs on Nasdaq at about $174.90 and in London around 13,300 pence as of 06/18/2026, 16:00 ET and 06/19/2026, 11:00 BST respectively.
Key facts on AstraZeneca stock
- Company: AstraZeneca PLC
- ISIN: US6549022043
- WKN: 886455
- Ticker: AZN
- Venue: Nasdaq (ADR) / London Stock Exchange
- Price (as of 06/18/2026, 16:00 ET): 174.90 USD (ADR)
- Market cap: about 269,000,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: FTSE 100, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
